한글목차

세계 디프테리아 백신 시장의 미래는 병원, 클리닉, 예방접종 센터 시장에서의 기회로 인해 유망합니다. 세계 디프테리아 백신 시장은 2025-2031년 6.5%의 연평균 복합 성장률(CAGR)로 2031년까지 약 80억 달러에 달할 것으로 예측됩니다. 이 시장의 주요 촉진요인은 혼합 백신에 대한 수요 증가, 디프테리아 백신 접종의 중요성에 대한 인식 증가, 디프테리아 백신 접종 프로그램을 추진하기 위한 정부 구상 증가입니다.

• Lucintel의 예측에 따르면 백신 유형별로는 디프테리아, 파상풍, 백일해 예방에 널리 사용되는 DTaP 백신이 여전히 가장 큰 비중을 차지할 것으로 보입니다.
• 최종 용도별로는 병원이 디프테리아 예방접종을 받는 가장 일반적인 장소이기 때문에 병원이 가장 큰 부문으로 남을 것으로 보입니다.
• 지역별로는 예방접종을 받지 않은 사람들 사이에서 디프테리아 사례가 증가하고 주요 제조업체가 이 지역에 존재하므로 북미가 예측 기간 중 가장 높은 성장세를 보일 것으로 예측됩니다.

디프테리아 백신 시장의 전략적 성장 기회

디프테리아 백신 시장의 전략적 성장 기회는 기술 발전, 공중보건 요구의 진화, 세계 백신 접종 구상의 확대에서 비롯되고 있습니다. 이러한 기회를 포착하면 시장 성장과 공중보건 향상에 큰 도움이 될 수 있습니다.

• 신흥 시장 진출: 헬스케어 수요가 증가하고 있는 신흥 시장을 공략하는 것은 큰 기회가 될 수 있습니다. 이들 지역에서 백신에 대한 접근성과 접근성을 향상시킴으로써 기업은 시장 접근성을 높이고 세계 질병 예방 노력에 기여할 수 있습니다.
• 새로운 백신 제제 개발: 개량형 혼합백신, 개량형 보조제 등 새로운 백신 제제 개발에 대한 투자는 성장 잠재력을 제공합니다. 이러한 혁신은 백신의 효능을 높이고, 부작용을 줄이며, 공중보건의 변화하는 요구에 대응할 수 있습니다.
• 디지털 헬스 기술과의 통합: 전자건강기록 및 모바일 앱과 같은 디지털 헬스 기술을 활용하여 백신 접종 추적 및 환자 참여를 향상시킬 수 있습니다. 이러한 통합은 컴플라이언스를 강화하고 적시에 백신을 투여할 수 있게 함으로써 전체 시장의 성장을 가속할 수 있습니다.
• 부스터 투여 프로그램의 중요성: 부스터 투여 프로그램의 개발 및 홍보를 통해 면역력 저하를 해결하고 장기적인 예방 효과를 높일 수 있습니다. 부스터 투여의 중요성을 강조함으로써 기업은 수요를 자극하고 다양한 인구 집단에서 백신 접종률을 높일 수 있습니다.
• 세계 예방접종 구상 강화: 중저소득 국가의 백신 접근성 및 형평성을 개선하기 위한 세계 예방접종 구상과 협력 체계를 지원하는 것은 성장의 기회가 될 수 있습니다. 이러한 노력은 세계 보건 목표에 기여하고 백신 제조업체에 새로운 시장을 창출할 수 있습니다.

이러한 전략적 성장 기회는 디프테리아 백신 시장의 잠재적 성장 잠재력을 강조합니다. 신흥 시장, 새로운 제형, 디지털 통합, 부스터 프로그램, 세계 구상에 집중함으로써 기업은 시장 동향을 활용하고 성장을 가속할 수 있습니다.

디프테리아 백신 시장 성장 촉진요인 및 과제

디프테리아 백신 시장은 기술 발전, 경제적 요인, 규제 문제 등 다양한 시장 성장 촉진요인 및 과제에 영향을 받고 있습니다. 이러한 요인을 이해하는 것은 시장을 탐색하고 성장 기회를 활용하는 데 있으며, 매우 중요합니다.

디프테리아 백신 시장을 촉진하는 요인은 다음과 같습니다.

• 기술 발전: 개량형 제형과 혼합 백신 등 백신 기술의 혁신이 시장 성장의 원동력이 되고 있습니다. 이러한 발전은 백신의 효능, 안전성, 투여 용이성을 향상시켜 백신의 광범위한 채택과 효과에 기여하고 있습니다.
• 인식과 수요 증가: 디프테리아 백신 접종의 중요성에 대한 인식이 높아지고 예방 위생 조치에 대한 수요가 증가하면서 시장 확대의 원동력이 되고 있습니다. 공공 교육 및 보건 캠페인은 백신 접종률 향상과 질병 예방 개선에 기여하고 있습니다.
• 정부 지원 및 정책: 자금 지원, 보조금, 백신 접종 지침 업데이트와 같은 정부 지원은 백신 개발 및 채택을 촉진하고 있습니다. 공중보건 향상과 질병 예방을 위한 정책은 시장 성장에 기여하고 있습니다.
• 연구개발에 대한 투자: 백신 연구개발에 대한 막대한 투자는 기술 혁신과 새로운 백신의 도입을 가속화합니다. 정부, 비상장 기업, 연구기관의 자금 지원은 시장 확대를 지원하고 기술 진보를 촉진합니다.
• 유통 네트워크 강화: 물류 및 인프라를 포함한 백신 유통 네트워크의 개선은 접근성과 커버리지를 향상시킵니다. 효율적인 공급망과 유통 시스템은 보다 광범위한 백신 접근을 촉진하고 시장 성장을 지원합니다.

디프테리아 백신 시장이 해결해야 할 과제는 다음과 같습니다.

• 높은 개발 및 생산 비용: 백신 개발 및 생산과 관련된 높은 비용은 시장 성장의 장벽이 될 수 있습니다. 이러한 비용은 특히 저소득 지역과 신흥 시장에서 가격 책정 및 접근성에 영향을 미칠 수 있습니다.
• 규제 및 컴플라이언스 문제: 복잡한 규제 요건을 극복하고 지역마다 다른 기준을 준수하는 것은 어려운 일입니다. 규제 장애물은 시장 진입, 제품 가용성, 전체 시장 역학에 영향을 미칠 수 있습니다.
• 백신에 대한 망설임과 수용: 백신에 대한 망설임과 안전성에 대한 우려는 시장 성장에 영향을 미칠 수 있습니다. 일반 대중의 인식과 잘못된 정보가 백신 접종률을 저해하고 전체 시장 역학에 영향을 미칠 수 있습니다.

이러한 촉진요인과 과제는 성장 기회를 형성하고 시장 역학에 영향을 미침으로써 디프테리아 백신 시장에 영향을 미칩니다. 기술 발전, 인지도 향상, 정부 지원, R&D 투자, 유통 강화는 성장을 가속하는 반면, 높은 비용, 규제 문제, 백신 접종에 대한 주저함 등은 과제로 작용하고 있습니다. 디프테리아 백신 시장에서 성공하기 위해서는 이러한 요인들을 해결하는 것이 필수적입니다.

목차

제1장 개요

제2장 세계의 디프테리아 백신 시장 : 시장 역학

• 서론, 배경, 분류
• 공급망
• 업계의 촉진요인과 과제

제3장 시장 동향과 예측 분석(2019-2031년)

• 거시경제 동향(2019-2024년)과 예측(2025-2031년)
• 세계의 디프테리아 백신 시장 동향(2019-2024년)과 예측(2025-2031년)
• 세계의 디프테리아 백신 시장 : 백신 유형별
  • DTaP 백신
  • DT 백신
  • Tdap 백신
  • Td 백신
• 세계의 디프테리아 백신 시장 : 최종 용도별
  • 병원
  • 클리닉
  • 백신 접종 센터
  • 기타

제4장 지역별 시장 동향과 예측 분석(2019-2031년)

• 세계의 디프테리아 백신 시장 : 지역별
• 북미의 디프테리아 백신 시장
• 유럽의 디프테리아 백신 시장
• 아시아태평양의 디프테리아 백신 시장
• 기타 지역의 디프테리아 백신 시장

제5장 경쟁 분석

• 제품 포트폴리오 분석
• 운영 통합
• Porter's Five Forces 분석

제6장 성장 기회와 전략 분석

• 성장 기회 분석
  • 세계의 디프테리아 백신 시장의 성장 기회 : 백신 유형별
  • 세계의 디프테리아 백신 시장의 성장 기회 : 최종 용도별
  • 세계의 디프테리아 백신 시장의 성장 기회 : 지역별
• 세계의 디프테리아 백신 시장의 새로운 동향
• 전략적 분석
  • 신제품 개발
  • 세계의 디프테리아 백신 시장의 생산능력 확대
  • 세계의 디프테리아 백신 시장에서의 기업인수합병(M&A), 합병사업
  • 인증과 라이선싱

제7장 주요 기업의 개요

• AJ Vaccines
• BIONET
• GlaxoSmithKline
• MassBiologics
• Merck & Co
• Panacea Biotech
• Sanofi
• Serum Institute India
• Bharat Biotech
• Meiji

영문목차

The future of the global diphtheria vaccine market looks promising with opportunities in the hospital, clinic, and vaccination center markets. The global diphtheria vaccine market is expected to reach an estimated $8 billion by 2031 with a CAGR of 6.5% from 2025 to 2031. The major drivers for this market are increasing demand for combination vaccines, rising awareness of the importance of diphtheria vaccination, and growing government initiatives to promote diphtheria vaccination programs.

• Lucintel forecasts that, within the vaccine type category, the DTaP vaccine will remain the largest segment due to its wide usage to protect against diphtheria, tetanus, and pertussis.
• Within the end use category, hospital will remain the largest segment as it's a common place where people get vaccinated against diphtheria.
• In terms of regions, North America is expected to witness the highest growth over the forecast period due to rising cases of diphtheria among unvaccinated people and the presence of key manufacturers in the region.

Gain valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Diphtheria Vaccine Market

Emerging trends in the diphtheria vaccine market reflect advancements in vaccine technology, evolving public health strategies, and changing global health dynamics. These trends are shaping how diphtheria vaccines are developed, distributed, and utilized.

• Increased Use of Combination Vaccines: The trend toward using combination vaccines, such as DTP (Diphtheria, Tetanus, Pertussis), is growing. Combining vaccines simplifies immunization schedules and improves compliance by reducing the number of shots required. This approach also helps in maintaining high vaccination rates and comprehensive protection against multiple diseases.
• Advancements in Vaccine Formulations: Innovations in vaccine formulations, including improved adjuvants and stabilization techniques, are enhancing vaccine efficacy and safety. New formulations aim to provide longer-lasting protection with fewer side effects, making vaccines more effective and easier to administer.
• Focus on Booster Doses: There is increasing emphasis on administering booster doses to maintain long-term immunity. Updated vaccination schedules are incorporating more frequent boosters to address waning immunity and ensure continued protection against diphtheria, particularly in adults and high-risk populations.
• Integration with Digital Health Technologies: Digital health technologies are being integrated into vaccination programs to improve tracking, reminders, and data management. Mobile apps and electronic health records are enhancing patient engagement and ensuring that individuals receive timely vaccinations and boosters.
• Global Vaccination Initiatives: Global vaccination initiatives are focusing on improving diphtheria vaccination coverage in low- and middle-income countries. Efforts to address vaccine inequities and increase access to diphtheria vaccines are critical in preventing outbreaks and achieving global health goals.

These emerging trends are reshaping the diphtheria vaccine market by advancing vaccine technology, enhancing formulation efficacy, increasing the focus on boosters, integrating digital tools, and supporting global vaccination efforts. These factors contribute to more effective and accessible vaccination programs, ultimately improving public health outcomes.

Recent Developments in the Diphtheria Vaccine Market

Recent developments in the diphtheria vaccine market include technological advancements, policy updates, and increased focus on global vaccination coverage. These developments are driving improvements in vaccine efficacy, accessibility, and public health strategies.

• Advancement in Combination Vaccines: Recent advancements include the development of more effective combination vaccines, such as the DTP vaccine, which combines diphtheria, tetanus, and pertussis protection in a single shot. This approach simplifies immunization schedules and improves vaccine uptake by reducing the number of required doses.
• New Vaccine Formulations: Improved vaccine formulations have been introduced to enhance efficacy and reduce side effects. These formulations incorporate new adjuvants and stabilization technologies, providing better protection against diphtheria and ensuring longer-lasting immunity.
• Enhanced Vaccination Guidelines: Many countries, including the United States and Germany, have updated their vaccination guidelines to include more frequent booster doses. These updates aim to address waning immunity and ensure continued protection, particularly in high-risk groups and older adults.
• Expansion of Vaccine Access: Efforts to expand vaccine access in underserved regions, such as rural India and low-income countries, have been strengthened. New distribution networks and public health campaigns are improving vaccine availability and coverage, helping to prevent diphtheria outbreaks.
• Integration of Digital Tools: The integration of digital health tools into vaccination programs is enhancing tracking, reminders, and data management. Mobile apps and electronic health records are being used to improve vaccination compliance and ensure timely administration of doses.

These recent developments are driving progress in the diphtheria vaccine market by advancing technology, improving formulations, updating guidelines, expanding access, and integrating digital tools. These factors contribute to more effective vaccination programs and better public health outcomes.

Strategic Growth Opportunities for Diphtheria Vaccine Market

Strategic growth opportunities in the diphtheria vaccine market are emerging from advancements in technology, evolving public health needs, and expanding global vaccination initiatives. Identifying these opportunities can lead to significant market growth and improved public health outcomes.

• Expansion into Emerging Markets: Targeting emerging markets with growing healthcare needs presents a significant opportunity. By improving vaccine access and availability in these regions, companies can expand their market reach and contribute to global disease prevention efforts.
• Development of New Vaccine Formulations: Investing in the development of new vaccine formulations, such as enhanced combination vaccines or improved adjuvants, offers growth potential. These innovations can increase vaccine efficacy, reduce side effects, and meet evolving public health needs.
• Integration with Digital Health Technologies: Leveraging digital health technologies, such as electronic health records and mobile apps, can improve vaccination tracking and patient engagement. This integration enhances compliance and ensures timely administration of vaccines, supporting overall market growth.
• Focus on Booster Dose Programs: Developing and promoting booster dose programs can address waning immunity and improve long-term protection. By emphasizing the importance of booster doses, companies can drive demand and enhance vaccination coverage in various populations.
• Strengthening Global Vaccination Initiatives: Supporting global vaccination initiatives and collaborations to improve vaccine access and equity in low- and middle-income countries presents growth opportunities. These efforts contribute to global health goals and create new markets for vaccine manufacturers.

These strategic growth opportunities highlight potential areas for expansion in the diphtheria vaccine market. By focusing on emerging markets, new formulations, digital integration, booster programs, and global initiatives, companies can capitalize on market trends and drive growth.

Diphtheria Vaccine Market Driver and Challenges

The diphtheria vaccine market is influenced by various drivers and challenges, including technological advancements, economic factors, and regulatory issues. Understanding these factors is crucial for navigating the market and leveraging growth opportunities.

The factors responsible for driving the diphtheria vaccine market include:

• Technological Advancements: Innovations in vaccine technology, such as improved formulations and combination vaccines, drive market growth. These advancements enhance vaccine efficacy, safety, and ease of administration, contributing to broader adoption and effectiveness.
• Increased Awareness and Demand: Growing awareness of the importance of diphtheria vaccination and increased demand for preventive health measures are driving market expansion. Public education and health campaigns are promoting higher vaccination rates and improving disease prevention.
• Government Support and Policies: Government support, including funding, subsidies, and updated vaccination guidelines, encourages vaccine development and adoption. Policies aimed at improving public health and disease prevention contribute to market growth.
• Investment in Research and Development: Significant investment in vaccine research and development accelerates innovation and the introduction of new vaccines. Funding from governments, private companies, and research institutions supports market expansion and drives technological progress.
• Enhanced Distribution Networks: Improvements in vaccine distribution networks, including logistics and infrastructure, enhance access and coverage. Efficient supply chains and distribution systems facilitate broader vaccine availability and support market growth.

Challenges in the diphtheria vaccine market are:

• High Development and Production Costs: High costs associated with vaccine development and production can be a barrier to market growth. These costs impact pricing and accessibility, particularly in low-income regions and emerging markets.
• Regulatory and Compliance Issues: Navigating complex regulatory requirements and ensuring compliance with varying standards across regions can be challenging. Regulatory hurdles can affect market entry, product availability, and overall market dynamics.
• Vaccine Hesitancy and Acceptance: Vaccine hesitancy and concerns about vaccine safety can impact market growth. Public perception and misinformation may hinder vaccination rates and affect overall market dynamics.

These drivers and challenges impact the diphtheria vaccine market by shaping growth opportunities and influencing market dynamics. Technological advancements, increased awareness, government support, investment in R&D, and enhanced distribution drive growth, while high costs, regulatory issues, and vaccine hesitancy present challenges. Addressing these factors is essential for success in the diphtheria vaccine market.

List of Diphtheria Vaccine Companies

Companies in the market compete based on product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies, diphtheria vaccine companies cater to increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the diphtheria vaccine companies profiled in this report include-

• AJ Vaccines
• BIONET
• GlaxoSmithKline
• MassBiologics
• Merck & Co
• Panacea Biotech
• Sanofi
• Serum Institute India
• Bharat Biotech
• Meiji

Diphtheria Vaccine by Segment

The study includes a forecast for the global diphtheria vaccine market by vaccine type, end use, and region.

Diphtheria Vaccine Market by Vaccine Type [Analysis by Value from 2019 to 2031]:

• DTaP Vaccine
• DT Vaccine
• Tdap Vaccine
• Td Vaccine

Diphtheria Vaccine Market by End Use [Analysis by Value from 2019 to 2031]:

• Hospitals
• Clinics
• Vaccination Centers
• Others

Diphtheria Vaccine Market by Region [Analysis by Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Diphtheria Vaccine Market

There is increasing coordination for vaccinations and new health challenges, due to which the diphtheria vaccine market is making remarkable improvements. The current shifts are determined by the advancement of technologies, the revision of vaccination policies, and the changing epidemiology. In the major market regions such as the USA, China, Germany, India, and Japan considerable progress has been made in vaccine development, policy revisions, and diphtheria public health strategies.

• United States: In the United States particularly, in the diphtheria vaccine market, recent changes have been listed as the improvement of the DTP (Diphtheria, Tetanus, Pertussis) combination vaccine and its wider use in adult booster doses. In developing countries there is emphasis in including diphtheria as part of routine childhood vaccines as well as enhance the surveillance systems of the vaccine. Reports from the CDC indicate that the guidelines have been adjusted over time to account for new strains.
• China: There has been progress in increasing diphtheria vaccination coverage in China especially on the primary doses and booster doses. Recent developments are reasons such as new vaccines that have been developed and activities like improved transportation of the available vaccines. Furthermore, the China's government has redoubled health education campaigns to promote diphtheria vaccination among children and adults.
• Germany: Germany has updated its vaccination guidelines to include more robust recommendations for diphtheria boosters, especially for older adults and travelers. Recent developments also focus on refining vaccine formulations to increase efficacy and reduce adverse reactions. The country is leveraging advancements in vaccine technology and research to enhance its diphtheria vaccination program and integrate it with broader immunization strategies.
• India: In India, there has been significant progress in expanding diphtheria vaccination coverage, particularly in rural and underserved areas. Recent developments include the roll-out of improved vaccine formulations and increased efforts to boost vaccination rates through public health campaigns and mobile vaccination units. The Indian government is also working to strengthen its immunization infrastructure and ensure better access to vaccines across the country.
• Japan: Japan has recently updated its diphtheria vaccination schedule to include more frequent booster doses, particularly for older adults and individuals at higher risk. Advances in vaccine technology and formulation are also being integrated into Japan's vaccination programs. The Japanese government continues to focus on public education and awareness campaigns to improve vaccine uptake and prevent outbreaks.

Features of the Global Diphtheria Vaccine Market

Market Size Estimates: Diphtheria vaccine market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.

Segmentation Analysis: Diphtheria vaccine market size by vaccine type, end use, and region in terms of value ($B).

Regional Analysis: Diphtheria vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different vaccine types, end uses, and regions for the diphtheria vaccine market.

Strategic Analysis: This includes M&A, new product development, and the competitive landscape of the diphtheria vaccine market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M&A, and more.

This report answers the following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the diphtheria vaccine market by vaccine type (DTaP vaccine, DT vaccine, Tdap vaccine, and Td vaccine), end use (hospitals, clinics, vaccination centers, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Diphtheria Vaccine Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

• 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
• 3.2. Global Diphtheria Vaccine Market Trends (2019-2024) and Forecast (2025-2031)
• 3.3: Global Diphtheria Vaccine Market by Vaccine Type
  • 3.3.1: DTaP Vaccine
  • 3.3.2: DT Vaccine
  • 3.3.3: Tdap vaccine
  • 3.3.4: Td vaccine
• 3.4: Global Diphtheria Vaccine Market by End Use
  • 3.4.1: Hospitals
  • 3.4.2: Clinics
  • 3.4.3: Vaccination centers
  • 3.4.4: Others

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

• 4.1: Global Diphtheria Vaccine Market by Region
• 4.2: North American Diphtheria Vaccine Market
  • 4.2.1: North American Market by Vaccine Type: DTaP Vaccine, DT Vaccine, Tdap vaccine, and Td vaccine
  • 4.2.2: North American Market by End Use: Hospitals, Clinics, Vaccination centers, and Others
• 4.3: European Diphtheria Vaccine Market
  • 4.3.1: European Market by Vaccine Type: DTaP Vaccine, DT Vaccine, Tdap vaccine, and Td vaccine
  • 4.3.2: European Market by End Use: Hospitals, Clinics, Vaccination centers, and Others
• 4.4: APAC Diphtheria Vaccine Market
  • 4.4.1: APAC Market by Vaccine Type: DTaP Vaccine, DT Vaccine, Tdap vaccine, and Td vaccine
  • 4.4.2: APAC Market by End Use: Hospitals, Clinics, Vaccination centers, and Others
• 4.5: ROW Diphtheria Vaccine Market
  • 4.5.1: ROW Market by Vaccine Type: DTaP Vaccine, DT Vaccine, Tdap vaccine, and Td vaccine
  • 4.5.2: ROW Market by End Use: Hospitals, Clinics, Vaccination centers, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Diphtheria Vaccine Market by Vaccine Type
  • 6.1.2: Growth Opportunities for the Global Diphtheria Vaccine Market by End Use
  • 6.1.3: Growth Opportunities for the Global Diphtheria Vaccine Market by Region
• 6.2: Emerging Trends in the Global Diphtheria Vaccine Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Diphtheria Vaccine Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Diphtheria Vaccine Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: AJ Vaccines
• 7.2: BIONET
• 7.3: GlaxoSmithKline
• 7.4: MassBiologics
• 7.5: Merck & Co
• 7.6: Panacea Biotech
• 7.7: Sanofi
• 7.8: Serum Institute India
• 7.9: Bharat Biotech
• 7.10: Meiji